Chardan Capital Maintains Buy on Taysha Gene Therapies, Maintains $12 Price Target

Benzinga · 5d ago
Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $12 price target.